Patent Grant
11896465
Embodiments of the present disclosure relate to methods and apparatuses for dressing and treating a wound with negative or reduced pressure therapy or topical negative pressure (TNP) therapy. In particular, but without limitation, embodiments disclosed herein relate to negative pressure therapy devices, methods for controlling the operation of TNP systems, and methods of using TNP systems.
In some embodiments, an apparatus for applying negative pressure is disclosed. The apparatus can include a wound dressing, a negative pressure source, a user interface, a first sensor, and control circuitry. The wound dressing can be placed over a wound of a patient. The negative pressure source can be disposed on or within the wound dressing, and the negative pressure source can provide negative pressure to the wound dressing via a fluid flow path. The user interface can receive an activation input. The first sensor can be integrated with the wound dressing, and the first sensor can detect whether the wound dressing is positioned over the wound. The control circuitry can be electrically coupled to the user interface and the first sensor, and the control circuitry can: cause supply of negative pressure with the negative pressure source in response to receipt of the activation input by the user interface and a determination that the first sensor detects that the wound dressing is positioned over the wound, and prevent supply of negative pressure with the negative pressure source in response to a determination that the first sensor does not detect that the wound dressing is positioned over the wound.
The apparatus of the preceding paragraph can include one or more of the following features: The control circuitry can further: start a timer in response to receipt of the activation input by the user interface and the determination that the first sensor detects that the wound dressing is positioned over the wound; and prevent supply of negative pressure with the negative pressure source in response to expiration of the timer. The control circuitry can further not start the timer in response to the determination that the first sensor does not detect that the wound dressing is positioned over the wound. The timer can expire after between 5 days and 20 days. The apparatus can further include a power source configured to supply power to one or more of the negative pressure source or the control circuitry, and the control circuitry can further increase an amount of power supplied by the power source in response to expiration of the timer. The control circuitry can prevent supply of negative pressure with the negative pressure source by one or more of: deactivation of operation of the negative pressure source, opening of a vent positioned in the fluid flow path, and closing of a valve positioned in the fluid flow path. The control circuitry can: supply negative pressure with the negative pressure source in response to receipt of the activation input by the user interface and the determination that the first sensor detects that the wound dressing is positioned over the wound for a first period of time, and prevent supply of negative pressure with the negative pressure source in response to the determination that the first sensor detects that the wound dressing is positioned over the wound for less than the first period of time. The first sensor can include one or more of a capacitive sensor, an impedance sensor, an optical sensor, a piezoresistive sensor, a piezoelectric sensor, an elastoresistive sensor, or an electrochemical sensor. The activation input can be indicative of an element of the user interface being depressed for a second period of time. The second period of time can be between 0.5 seconds and 5 seconds. The user interface can receive a deactivation input, and in response to receipt of the deactivation input by the user interface while the negative pressure source supplies negative pressure, the control circuitry can prevent supply of negative pressure with the negative pressure source. The deactivation input can be indicative of an element of the user interface being depressed for a second period of time, and the activation input is indicative of the element of the user interface being depressed for a third period of time. The second period of time and the third period of time can each be between 0.5 seconds and 5 seconds. The control circuitry can determine if the first sensor detects that the wound dressing is positioned over the wound in response to receipt of the activation input by the user interface. The apparatus can further include: a second sensor configured to monitor pressure in the fluid flow path, and a third sensor configured to monitor pressure outside the wound dressing, and wherein the control circuitry can further control supply of negative pressure with the negative pressure source according at least to a comparison of the pressure monitored by the second sensor and the pressure monitored by the third sensor. The control circuitry can further: determine a magnitude of a difference between the pressure monitored by the second sensor and the pressure monitored by the third sensor; prevent supply of negative pressure with the negative pressure source in response to a determination that the magnitude satisfies a deactivation threshold; and supply negative pressure with the negative pressure source in response to a determination that the magnitude satisfies an activation threshold, the deactivation threshold being different from the activation threshold. The control circuitry can further: sample the pressure monitored by the second sensor and the pressure monitored by the third sensor; and vary a sampling rate at which the pressure monitored by the second sensor and the pressure monitored by the third sensor are sampled. The control circuitry can vary the sampling rate according to one or more of (i) an amount of energy stored in a power source used to power the negative pressure source or the control circuitry or (ii) whether the negative pressure source is supplying negative pressure. The control circuitry can further enter a sleep mode, and the control circuitry can vary the sampling rate by entering the sleep mode. The control circuitry can further enter a sleep mode in which the control circuitry does not sample the pressure monitored by the second sensor and the pressure monitored by the third sensor until the control circuitry leaves the sleep mode. The control circuitry can further awaken from the sleep mode in response to receipt of a hardware interrupt or a software interrupt. The control circuitry can enter a sleep mode in response to the determination that the first sensor does not detect that the wound dressing is positioned over the wound. The control circuitry can enter a sleep mode while the negative pressure source supplies negative pressure. The control circuitry can further receive the user input from the user interface as a hardware interrupt.
A method of operating, using, or manufacturing the apparatus of the preceding two paragraphs is also disclosed.
In some embodiments, a method of operating a negative pressure wound therapy apparatus is disclosed. The negative pressure wound therapy apparatus can include a wound dressing, a negative pressure source disposed on or within the wound dressing, a user interface, and a first sensor integrated with the wound dressing. The method can include: receiving an activation input with the user interface; determining whether the first sensor detects that the wound dressing is positioned over a wound; in response to receiving the activation input and determining that the first sensor detects that the wound dressing is positioned over the wound, supplying negative pressure with the negative pressure source to the wound dressing via a fluid flow path; and in response to determining that the first sensor does not detect that the wound dressing is positioned over the wound, preventing supply of negative pressure with the negative pressure source to the wound dressing.
The method of the preceding paragraph can include one or more of the following features: The method can further include: starting a timer in response to receiving the activation input with the user interface and determining that the first sensor detects that the wound dressing is positioned over the wound; and preventing supply of negative pressure with the negative pressure source to the wound dressing in response to expiration of the timer. The activation input can be indicative of an element of the user interface being depressed for a second period of time. The second period of time can be between 0.5 seconds and 5 seconds. The determining whether the first sensor detects that the wound dressing can be performed in response to receiving the activation input with the user interface. The supplying negative pressure with the negative pressure source can be controlled according at least to a comparison of a pressure monitored by a second sensor and a pressure monitored by a third sensor, the second sensor monitoring the pressure in the fluid flow path, the third sensor monitoring the pressure outside the wound dressing. The method can further include: sampling a pressure monitored by a second sensor and a pressure monitored by a third sensor, the second sensor monitoring the pressure in the fluid flow path, the third sensor monitoring the pressure outside the wound dressing; and varying a sampling rate at which the pressure monitored by the second sensor and the pressure monitored by the third sensor are sampled according to one or more of: (i) an amount of energy stored in a power source used to power the negative pressure source or the control circuitry and (ii) whether the negative pressure source is supplying negative pressure.
Features and advantages of the present disclosure will be apparent from the following detailed description, taken in conjunction with the accompanying drawings of which:
The present disclosure relates to methods and apparatuses for dressing and treating a wound with reduced pressure therapy or topical negative pressure (TNP) therapy. In particular, but without limitation, embodiments of this disclosure relate to negative pressure therapy apparatuses, methods for controlling the operation of TNP systems, and methods of using TNP systems. The methods and apparatuses can incorporate or implement any combination of the features described below.
Many different types of wound dressings are known for aiding in the healing process of a human or animal. These different types of wound dressings include many different types of materials and layers, for example, gauze, pads, foam pads or multi-layer wound dressings. TNP therapy, sometimes referred to as vacuum assisted closure, negative pressure wound therapy, or reduced pressure wound therapy, can be a beneficial mechanism for improving the healing rate of a wound. Such therapy is applicable to a broad range of wounds such as incisional wounds, open wounds and abdominal wounds or the like.
TNP therapy can assist in the closure and healing of wounds by reducing tissue oedema, encouraging blood flow, stimulating the formation of granulation tissue, removing excess exudates, and reducing bacterial load and thus, infection to the wound. Furthermore, TNP therapy can permit less outside disturbance of the wound and promote more rapid healing.
As is used herein, reduced or negative pressure levels, such as −X mmHg, represent pressure levels that are below atmospheric pressure, which typically corresponds to 760 mmHg (or 1 atm, 29.93 inHg, 101.325 kPa, 14.696 psi, etc.). Accordingly, a negative pressure value of −X mmHg reflects pressure that is X mmHg below atmospheric pressure, such as a pressure of (760−X) mmHg. In addition, negative pressure that is “less” or “smaller” than −X mmHg corresponds to pressure that is closer to atmospheric pressure (e.g., −40 mmHg is less than −60 mmHg). Negative pressure that is “more” or “greater” than −X mmHg corresponds to pressure that is further from atmospheric pressure (e.g., −80 mmHg is more than −60 mmHg).
Overview
Control circuitry of a TNP apparatus can delay activation of negative pressure or other functions of the TNP apparatus until after the TNP apparatus confirms contact with skin of a patient. In one example, a TNP apparatus can include a wound dressing with an integrated sensor configured to detect whether the wound dressing is in contact with skin of a patient. The TNP apparatus may not provide negative pressure to the wound dressing until the wound dressing is detected to be in contact with skin. Moreover, the TNP apparatus can provide negative pressure to the wound dressing in response to detecting that the wound dressing is in contact with skin. Additionally or alternatively, the TNP apparatus can delay activation of an end-of-life timer for the TNP apparatus until contact with skin of a patient is detected.
A TNP apparatus can determine pressure underneath a wound dressing relative to pressure external to the wound dressing. The TNP apparatus can, for instance, monitor pressure underneath the wound dressing using a first pressure sensor and monitor pressure external to the wound dressing using a second pressure sensor. The TNP apparatus can, in turn, control a negative pressure source of the TNP apparatus to attempt to achieve a desired pressure differential between the pressure underneath the wound dressing and the pressure external to the wound dressing. Control circuitry of the TNP apparatus can, in some instances, vary the sampling rate at which the pressures monitored by the first and second pressure sensors are sampled, such as to increase or decrease an amount of power consumed by the control circuitry.
Reduced Pressure Therapy Systems and Methods
One or more of the control circuitry 12A, memory device 12B, negative pressure source 12C, user interface 12D, power source 12E, first pressure sensor 12F, second pressure sensor 12G, and skin detector 12H can be integral with, incorporated as part of, attached to, or disposed in the wound dressing 13. The TNP apparatus 11 can accordingly be considered to have its control electronics and pump on-board the wound dressing 13 rather than separate from the wound dressing 13.
The control circuitry 12A can include one or more controllers (for example, a microcontroller or microprocessor), activation circuits, boost converters, current limiters, feedback conditioning circuits, and H-bridge inverters. The one or more controllers can control the operations of one or more other components of the TNP apparatus 11 according at least to instructions stored in the memory device 12B. The one or more controllers can, for instance, control operations of the negative pressure source 12C (for example, a pump) via a signal input (for example, a pulse width modulation (PWM) of the signal) to the one or more H-bridge inverters, which in turn drive power from the power source 12E to the negative pressure source 12C.
The negative pressure source 12C can include a pump, such as a rotary diaphragm pump or other diaphragm pump, a piezoelectric pump, a peristaltic pump, a piston pump, a rotary vane pump, a liquid ring pump, a scroll pump, a pump operated by a piezoelectric transducer, a voice coil pump, or any other suitable pump or micropump or any combinations of the foregoing. The pump can include an actuator driven by a source of energy, such as electrical energy, mechanical energy, and the like. For example, the actuator can be an electric motor, a piezoelectric transducer, a voice coil actuator, an electroactive polymer, a shape-memory alloy, a comb drive, a hydraulic motor, a pneumatic actuator, a screw jack, a servomechanism, a solenoid actuator, a stepper motor, a plunger, a combustion engine, and the like.
The user interface 12D can include one or more elements that receive user inputs or provide user outputs to a patient or caregiver. The one or more elements that receive user inputs can include buttons, switches, dials, touch screens, or the like, and the one or more elements that provide user outputs can include activation of a light emitting diode (LED) or one or more pixels of the display or activation of a speaker or the like. In one example, the user interface 12D can include a switch to receive user inputs (for instance, a negative pressure activation or deactivation input) and two LEDs to indicate an operating status (for example, functioning normally, under fault condition, or awaiting user input) of the TNP apparatus 11.
The first pressure sensor 12F can be used to monitor pressure underneath the wound dressing 13, such as pressure in a fluid flow path connecting the negative pressure source 12C and the wound 14, pressure at the wound 14, or pressure in the negative pressure source 12C. The second pressure sensor 12G can be used to monitor pressure external to the wound dressing 13. The pressure external to the wound dressing can be atmospheric pressure; however, the atmospheric pressure can vary depending on, for instance, an altitude of use or pressurized environment in which the TNP apparatus 11 may be used.
The control circuitry 12A can control the supply of negative pressure by the negative pressure source 12C according at least to a comparison between the pressure monitored by the first pressure sensor 12F and the pressure monitored by the second pressure sensor 12G. The control circuitry 12A can vary the sampling rate at which pressures monitored by the first and second pressure sensors 12F and 12G are sampled, such as based at least on an amount of energy stored in the power source 12E or whether the negative pressure source 12C is supplying negative pressure. The sampling rate can be varied, for instance, to increase an amount of power consumed (that is, by increasing the sampling rate) or decrease an amount of power consumed (that is, by decreasing the sampling rate) by the control circuitry 12A. A controller of the control circuitry 12A can enter a sleep mode, which may be a mode during which the pressure monitored by the first and second pressure sensors 12F and 12G is not sampled, and the controller can vary the sampling rate by entering the sleep mode. The sleep mode may be a mode from which the controller can be awoken via a hardware or software interrupt.
The skin detector 12H can be used to determine if the wound dressing 13 has been placed over the wound 14. For example, the skin detector 12H can be a part of the TNP apparatus 11 that makes contact with skin of a patient when the TNP apparatus 11 is placed on a patient to provide therapy, and the skin detector 12H can detect when the skin detector 12H is in contact with skin of a patient. The detection by the skin detector 12H can thus confirm whether the wound dressing 13 is coupled to skin of the patient next to the wound 14. The skin detector 12H can include one or more of a capacitive sensor, an impedance sensor, an optical sensor, a piezoresistive sensor, a piezoelectric sensor, an elastoresistive sensor, and an electrochemical sensor. The skin detector 12H can indicate detection of skin when a property (for instance, a resistance, capacitance, or color) monitored by the skin detector 12H varies in a way that indicates contact with skin rather than absence of contact with skin.
When skin is detected, this may indicate that activation of the TNP apparatus 11 is intentional rather than unintentional and can thus be used to prevent unintentional activation of the TNP apparatus 11 or an end-of-life timer of the TNP apparatus 11, such as during transportation or manufacture of the TNP apparatus 11. In one example, if the skin detector 12H indicates to the control circuitry 12A that skin is detected (for instance, in some cases, for a period of time like 0.1, 0.5, 1, 2, or 5 seconds), the control circuitry 12A can activate the negative pressure source 12C to supply negative pressure and activate an end-of-life timer in response to receiving an activation input via the user interface 12D. If the skin detector 12H, on the other hand, indicates to the control circuitry 12A that skin is not detected (for instance, in some cases, for a period of time like 0.1, 0.5, 1, 2, or 5 seconds), the control circuitry 12A may not activate the negative pressure source 12C to supply negative pressure or activate an end-of-life timer in response to receiving an activation input via the user interface 12D. In one example, an end-of-life timer can be a timer maintained by the control circuitry 12A that, while running, denotes that one or more functions of the TNP apparatus 11 (such as providing of negative pressure with the negative pressure source 12C or processing user inputs to the user interface 12D) is enabled. Upon expiration of the end-of-life timer (such as 1, 5, or 20 days after activation of the timer), the control circuitry 12A can disable the one or more functions of the TNP apparatus 11.
The wound dressing 13 can include a wound contact layer, a spacer layer, and an absorbent layer. The wound contact layer can be in contact with the wound 14. The wound contact layer can include an adhesive on the patient facing side for securing the dressing to the skin surrounding the wound 14 or on the top side for securing the wound contact layer to a cover layer or other layer of the wound dressing 13. In operation, the wound contact layer can provide unidirectional flow so as to facilitate removal of exudate from the wound while blocking or substantially preventing exudate from returning to the wound 14. The spacer layer can assist in distributing negative pressure over the wound site and facilitating transport of wound exudate and fluids into the wound dressing 13. Further, the absorbent layer can absorb and retain exudate aspirated from the wound 14.
The control circuitry 12A can cause the power source 12E to supply a greater amount of power upon expiration of an end-of-life timer to increase the rate at which the energy stored in the power supply 12E is exhausted. This may advantageously, in certain embodiments, make the TNP apparatus 11 safer to handle and dispose of after expiration of the end-of-life timer. In one example, the control circuitry 12A can close some or all of the switches of an H-bridge inverter to cause the H-bridge inverter to consume a greater amount of power.
The control circuitry 12A can, in some instances, prevent supply of negative pressure with the negative pressure source 12C. For example, the control circuitry 12A can prevent supply of negative pressure by deactivating operation of the negative pressure source, opening a vent positioned in the fluid flow path, and closing a valve positioned in the fluid flow path. In some implementations, the control circuitry 12A can prevent supply of negative pressure by the negative pressure source 12C in response determining that the skin detector 12H does not detect skin of the patient.
The control circuitry 12A can monitor a duty cycle of the negative pressure source 12C (for example, the duty cycle of the actuator of the negative pressure source). As is used herein, the “duty cycle” can reflect the amount of time the negative pressure source 12C is active or running over a period of time. In other words, the duty cycle can reflect time that the negative pressure source 12C is in an active state as a fraction of total time under consideration. Duty cycle measurements can reflect a level of activity of the negative pressure source 12C. For example, the duty cycle can indicate that the negative pressure source 12C is operating normally, working hard, working extremely hard, etc. Moreover, the duty cycle measurements, such as periodic duty cycle measurements, can reflect various operating conditions, such as presence or severity of leaks, rate of flow of fluid (for instance, air, liquid, or solid exudate, etc.) aspirated from a wound, or the like. Based on the duty cycle measurements, such as by comparing the measured duty cycle with a set of thresholds (for instance, determined in calibration), the controller can execute or be programmed to execute algorithms or logic that control the operation of the system. For example, duty cycle measurements can indicate presence of a high leak, and the control circuitry 12A can be programmed to indicate this condition to a user (for instance, patient, caregiver, or physician) or temporarily suspend or pause operation of the source of negative pressure in order to conserve power.
When the TNP apparatus 11 may be used to treat the wound 14, the wound dressing 13 can create a substantially sealed or closed space around the wound 13 and under the wound dressing 13, and the first pressure sensor 12F can periodically or continuously measure or monitor a level of pressure in this space. The control circuitry 12A can control the level of pressure in the space between a first negative pressure set point limit and at least a second negative pressure set point limit. In some instances, the first set point limit can be approximately −70 mmHg, or from approximately −60 mmHg or less to approximately −80 mmHg or more. In some instances, the second set point limit can be approximately −90 mmHg, or from approximately −80 mmHg or less to approximately −100 mmHg or more.
In the negative pressure therapy system 200, the wound dressing 13 of the TNP apparatus 11 is shown as attached to the wound 14. Arrows depict the flow of air through the wound dressing 13 and wound exudate from the wound 14. The TNP apparatus 11 can include an air exhaust 26 and a component area 25, such as a components housing or storage area for components of the TNP apparatus 11 like one or more of the control circuitry 12A, memory device 12B, negative pressure source 12C, user interface 12D, power source 12E, first pressure sensor 12F, and second pressure sensor 12G. The skin detector 12H can be positioned near a skin surface by the wound 14 and be electrically coupled to the control circuitry 12A to indicate whether skin is detected.
The user interface 12D of the negative pressure therapy system 200 can include a switch 21 (such as a dome switch), a first indicator 23 (such as a first LED), and a second indicator 24 (such as a second LED). The switch 21 can receive a negative pressure activation or deactivation user input (for example, such as receiving the activation or deactivation user input in response to depression of the switch 21 for a period of time, like from between 0.5 seconds and 5 seconds). The first indicator 23 and the second indicator 24 can indicate an operating status like functioning normally, under fault condition, or awaiting user input. In some implementations, the switch 21 can couple to a power supply connection of the negative pressure source 12C or the control circuitry 12A (such as a controller) or an enable signal of the negative pressure source 12C or the control circuitry 12A to activate or deactivate supply of negative pressure or disable supply of negative pressure.
Component parts of the wound dressing 13 of the negative pressure therapy system 200 are illustrated to include an airlock layer 27, an absorbing layer 28, and a contact layer 29. The airlock layer 27 can enable air flow. The absorbing layer 28 can absorb wound exudate. The contact layer 29 can be soft and include silicon and be used to couple the TNP apparatus 11 to the patient.
At state 31, the control circuitry 12A can power up. This can occur, for example, in response to the power source 12E being electrically coupled to the control circuitry 12A, such as by a user removing a tab that was electrically isolating the power source 12E and a controller of the control circuitry 12A so that the power source 12E and the controller are electrically coupled. At state 32, the control circuitry 12A can remain in an idle state, which can be a low power state where the controller consumes minimal power and draws minimal current (such as around 10, 30, 50, or 100 nA). When the switch 21 of the user interface 12D is pressed, the control state diagram 300 can transition to state 33, and the control circuitry 12A can initiate start-up. When the switch 21 is held less than a period of time T1 (such as 0.5, 1, 2, 3, or 5 seconds), the control circuitry 12A may enter a negative pressure supply operation phase that includes states 34 and 35. When the switch 21 is held for the period of time T1 or longer, the control state diagram 300 can transition to state 37, and the control circuitry 12A can initiate shut down and return to state 32.
Once in the negative pressure supply operation phase that includes states 34 and 35, the control circuitry 12A can attempt to deliver a desired level of negative pressure to the wound dressing 13 and control the supply of negative pressure with the negative pressure source 12C based at least on a magnitude of a pressure difference Pdiff between the pressure measured by the first pressure sensor 12F and the second pressure sensor 12G. For instance, at state 35, the control circuitry 12A can cause the negative pressure source 12C to supply negative pressure if Pdiff was be less than Pthres, such as 50, 70, 90, 93, 100, or 120 mBar. The control circuitry 12A can, for example, cause the negative pressure source 12C to supply negative pressure for a period of time T2 (such as 0.05, 0.1, 0.25, 0.5, 1, or 2 seconds) and then at state 34 stop the supply of negative pressure and again determine if Pdiff may be less than Pthres.
The control state diagram 300 can transition from states 34 and 35 to state 36, which can be indicative of a fault condition, when one or more operating parameters indicate that the negative pressure source 12C is operating too quickly or slowly or not operating as instructed. For example, the fault condition can be determined based on a level of activity of the negative pressure source 12C satisfying a threshold. In one implementation, duty cycle or PWM information can be monitored by the TNP apparatus 11 and compared to one or more thresholds (for instance, indicating whether a duty cycle protection may be exceeded or a PWM frequency may be out of bounds).
The control state diagram 300 can transition from state 36 to state 37 when the switch 21 is pressed and held for a period of time T3 (such as 0.5, 1, 2, 3, or 5 seconds) or longer. The control state diagram 300 can transition from state 34 to state 37 when the switch 21 is pressed and held for a period of time T4 (such as 0.5, 1, 2, 3, or 5 seconds) or longer. The control state diagram 300 can transition from state 35 to state 37 when no load may be detected (for example, detecting a condition where a connection issue exists between the control circuitry 12A and the negative pressure source 12C, such as by detecting if a voltage of the power source 12E drops below a threshold like 5 V). The control state diagram 300 can transition from state 36 to state 34 when a period of time T5 (such as 5, 10, 15, 20, 30, or 60 minutes) elapses without the switch 21 being pressed and held for the period of time T2 or longer. One or more of the periods of time T1, T3, and T4 can be the same or different from one another in some instances.
In some implementations, the first indicator 23 and the second indicator 24 can indicate which of the states 31-37 that the TNP apparatus 11 may be in via, for example, one or more of (i) activation or deactivation of one or both of the first indicator 23 and the second indicator 24 for period(s) of time or (ii) changing a color of the first indicator 23 or the second indicator 24.
At block 41, the therapy initiation process 400 can receive an activation input. For example, the control circuitry 12A can receive an activation input via the user interface 12D. The activation input can be an input to the user interface 12D indicating to initiate supply of negative pressure with the negative pressure source 12C.
At block 42, the therapy initiation process 400 can determine if skin is detected. For example, the control circuitry 12A can determine if skin is detected by the skin detector 12H.
In response to determining that skin is detected, the therapy initiation process 400 can move to block 43 and begin supply of negative pressure. For example, the control circuitry 12A can initiate the supply of negative pressure to the wound dressing 13. Moreover, in some implementations, the control circuitry 12A can start an end-of-life timer in response to determining that skin is detected and beginning supply of negative pressure for the first time. The end-of-life timer can enable the TNP apparatus 11 to treat a single wound and then deactivate (for example, permanently) upon expiration of the end-of-life timer so that the TNP apparatus 11 is not usable to treat another wound.
On the other hand, in response to determining that skin is not detected, the therapy initiation process 400 can end, and the control circuitry 12A, for instance, may not initiate the supply of negative pressure.
Other Variations
Any value of a threshold, limit, duration, etc. provided herein is not intended to be absolute and, thereby, can be approximate. In addition, any threshold, limit, duration, etc. provided herein can be fixed or varied either automatically or by a user. Furthermore, as is used herein relative terminology such as exceeds, greater than, less than, etc. in relation to a reference value is intended to also encompass being equal to the reference value. For example, exceeding a reference value that is positive can encompass being equal to or greater than the reference value. In addition, as is used herein relative terminology such as exceeds, greater than, less than, etc. in relation to a reference value is intended to also encompass an inverse of the disclosed relationship, such as below, less than, greater than, etc. in relations to the reference value. Moreover, although blocks of the various processes may be described in terms of determining whether a value meets or does not meet a particular threshold, the blocks can be similarly understood, for example, in terms of a value (i) being below or above a threshold or (ii) satisfying or not satisfying a threshold.
Features, materials, characteristics, or groups described in conjunction with a particular aspect, embodiment, or example are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract, and drawings), or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features or steps are mutually exclusive. The protection is not restricted to the details of any foregoing embodiments. The protection extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.
While certain embodiments have been described, these embodiments have been presented by way of example only, and are not intended to limit the scope of protection. Indeed, the novel methods and systems described herein may be embodied in a variety of other forms. Furthermore, various omissions, substitutions and changes in the form of the methods and systems described herein may be made. Those skilled in the art will appreciate that in some embodiments, the actual steps taken in the processes illustrated or disclosed may differ from those shown in the figures. Depending on the embodiment, certain of the steps described above may be removed, others may be added. For example, the actual steps or order of steps taken in the disclosed processes may differ from those shown in the figure. Depending on the embodiment, certain of the steps described above may be removed, others may be added. For instance, the various components illustrated in the figures may be implemented as software or firmware on a processor, controller, ASIC, FPGA, or dedicated hardware. Hardware components, such as processors, ASICs, FPGAs, and the like, can include logic circuitry. Furthermore, the features and attributes of the specific embodiments disclosed above may be combined in different ways to form additional embodiments, all of which fall within the scope of the present disclosure.
User interface screens illustrated and described herein can include additional or alternative components. These components can include menus, lists, buttons, text boxes, labels, radio buttons, scroll bars, sliders, checkboxes, combo boxes, status bars, dialog boxes, windows, and the like. User interface screens can include additional or alternative information. Components can be arranged, grouped, displayed in any suitable order.
Although the present disclosure includes certain embodiments, examples and applications, it will be understood by those skilled in the art that the present disclosure extends beyond the specifically disclosed embodiments to other alternative embodiments or uses and obvious modifications and equivalents thereof, including embodiments which do not provide all of the features and advantages set forth herein. Accordingly, the scope of the present disclosure is not intended to be limited by the specific disclosures of preferred embodiments herein, and may be defined by claims as presented herein or as presented in the future.
Conditional language, such as “can,” “could,” “might,” or “may,” unless specifically stated otherwise, or otherwise understood within the context as used, is generally intended to convey that certain embodiments include, while other embodiments do not include, certain features, elements, or steps. Thus, such conditional language is not generally intended to imply that features, elements, or steps are in any way required for one or more embodiments or that one or more embodiments necessarily include logic for deciding, with or without user input or prompting, whether these features, elements, or steps are included or are to be performed in any particular embodiment. The terms “comprising,” “including,” “having,” and the like are synonymous and are used inclusively, in an open-ended fashion, and do not exclude additional elements, features, acts, operations, and so forth. Also, the term “or” is used in its inclusive sense (and not in its exclusive sense) so that when used, for example, to connect a list of elements, the term “or” means one, some, or all of the elements in the list. Further, the term “each,” as used herein, in addition to having its ordinary meaning, can mean any subset of a set of elements to which the term “each” is applied.
Conjunctive language such as the phrase “at least one of X, Y, and Z,” unless specifically stated otherwise, is otherwise understood with the context as used in general to convey that an item, term, etc. may be either X, Y, or Z. Thus, such conjunctive language is not generally intended to imply that certain embodiments require the presence of at least one of X, at least one of Y, and at least one of Z.
Language of degree used herein, such as the terms “approximately,” “about,” “generally,” and “substantially” as used herein represent a value, amount, or characteristic close to the stated value, amount, or characteristic that still performs a desired function or achieves a desired result. For example, the terms “approximately”, “about”, “generally,” and “substantially” may refer to an amount that is within less than 10% of, within less than 5% of, within less than 1% of, within less than 0.1% of, and within less than 0.01% of the stated amount. As another example, in certain embodiments, the terms “generally parallel” and “substantially parallel” refer to a value, amount, or characteristic that departs from exactly parallel by less than or equal to 15 degrees, 10 degrees, 5 degrees, 3 degrees, 1 degree, or 0.1 degree.
The scope of the present disclosure is not intended to be limited by the specific disclosures of preferred embodiments in this section or elsewhere in this specification, and may be defined by claims as presented in this section or elsewhere in this specification or as presented in the future. The language of the claims is to be interpreted broadly based on the language employed in the claims and not limited to the examples described in the present specification or during the prosecution of the application, which examples are to be construed as non-exclusive.
This application is a continuation of U.S. patent application Ser. No. 16/098,625, filed Nov. 2, 2018, which is a U.S. national stage application of International Patent Application No. PCT/EP2017/060464, filed May 3, 2017, which claims the benefit of U.S. Provisional Application No. 62/331,056, filed May 3, 2016, and U.S. Provisional Application No. 62/479,615, filed Mar. 31, 2017; the disclosures of which are hereby incorporated by reference in their entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3874387 | Barbieri | Apr 1975 | A |
| 4224941 | Stivala | Sep 1980 | A |
| 4398910 | Blake et al. | Aug 1983 | A |
| 4534356 | Papadakis | Aug 1985 | A |
| 4569674 | Phillips et al. | Feb 1986 | A |
| 4624656 | Clark et al. | Nov 1986 | A |
| 4681562 | Beck et al. | Jul 1987 | A |
| 4767943 | Adler et al. | Aug 1988 | A |
| 4979944 | Luzsicza | Dec 1990 | A |
| 5055195 | Trasch et al. | Oct 1991 | A |
| 5055198 | Shettigar | Oct 1991 | A |
| 5056510 | Gilman | Oct 1991 | A |
| 5152757 | Eriksson | Oct 1992 | A |
| 5181905 | Flam | Jan 1993 | A |
| 5266928 | Johnson | Nov 1993 | A |
| D357743 | Bilitz et al. | Apr 1995 | S |
| 5527293 | Zamierowski | Jun 1996 | A |
| 5549584 | Gross | Aug 1996 | A |
| 5636643 | Argenta et al. | Jun 1997 | A |
| 5643189 | Masini | Jul 1997 | A |
| 5779657 | Daneshvar | Jul 1998 | A |
| 5833646 | Masini | Nov 1998 | A |
| 5902256 | Benaron | May 1999 | A |
| 5964723 | Augustine | Oct 1999 | A |
| 6071267 | Zamierowski | Jun 2000 | A |
| 6142982 | Hunt et al. | Nov 2000 | A |
| 6168800 | Dobos et al. | Jan 2001 | B1 |
| 6183438 | Berguer | Feb 2001 | B1 |
| 6225523 | Masini | May 2001 | B1 |
| 6261276 | Reitsma | Jul 2001 | B1 |
| 6261283 | Morgan et al. | Jul 2001 | B1 |
| 6398767 | Fleischmann | Jun 2002 | B1 |
| 6458109 | Henley et al. | Oct 2002 | B1 |
| 6471982 | Lydon et al. | Oct 2002 | B1 |
| 6599262 | Masini | Jul 2003 | B1 |
| 6607495 | Skalak et al. | Aug 2003 | B1 |
| 6685681 | Lockwood et al. | Feb 2004 | B2 |
| 6787682 | Gilman | Sep 2004 | B2 |
| 6794554 | Sessions et al. | Sep 2004 | B2 |
| 6800074 | Henley et al. | Oct 2004 | B2 |
| 6855135 | Lockwood et al. | Feb 2005 | B2 |
| 6942633 | Odland | Sep 2005 | B2 |
| 6951553 | Bubb et al. | Oct 2005 | B2 |
| 6979324 | Bybordi et al. | Dec 2005 | B2 |
| 7004915 | Boynton et al. | Feb 2006 | B2 |
| 7022113 | Lockwood et al. | Apr 2006 | B2 |
| 7067709 | Murata et al. | Jun 2006 | B2 |
| 7070584 | Johnson et al. | Jul 2006 | B2 |
| 7087806 | Scheinberg et al. | Aug 2006 | B2 |
| 7108683 | Zamierowski | Sep 2006 | B2 |
| 7128735 | Weston | Oct 2006 | B2 |
| 7338482 | Lockwood et al. | Mar 2008 | B2 |
| 7361184 | Joshi | Apr 2008 | B2 |
| 7524315 | Blott et al. | Apr 2009 | B2 |
| 7553306 | Hunt et al. | Jun 2009 | B1 |
| 7569742 | Haggstrom et al. | Aug 2009 | B2 |
| 7611500 | Lina et al. | Nov 2009 | B1 |
| 7615036 | Joshi et al. | Nov 2009 | B2 |
| D605775 | Koch et al. | Dec 2009 | S |
| D608007 | Arbesman et al. | Jan 2010 | S |
| 7645253 | Gura et al. | Jan 2010 | B2 |
| 7687678 | Jacobs | Mar 2010 | B2 |
| 7699823 | Haggstrom et al. | Apr 2010 | B2 |
| 7776028 | Miller et al. | Aug 2010 | B2 |
| D625422 | Arbesman et al. | Oct 2010 | S |
| 7815616 | Boehringer et al. | Oct 2010 | B2 |
| 7837673 | Vogel | Nov 2010 | B2 |
| 7846141 | Weston | Dec 2010 | B2 |
| 7896864 | Lockwood et al. | Mar 2011 | B2 |
| 7922676 | Daskal et al. | Apr 2011 | B2 |
| 7922703 | Riesinger | Apr 2011 | B2 |
| 7942866 | Radl et al. | May 2011 | B2 |
| 7959624 | Riesinger | Jun 2011 | B2 |
| 7976519 | Bubb et al. | Jul 2011 | B2 |
| 8007257 | Heaton et al. | Aug 2011 | B2 |
| 8007481 | Schuessler et al. | Aug 2011 | B2 |
| 8062272 | Weston | Nov 2011 | B2 |
| 8080702 | Blott et al. | Dec 2011 | B2 |
| 8092441 | Sugito | Jan 2012 | B2 |
| 8158844 | McNeil | Apr 2012 | B2 |
| 8167869 | Wudyka | May 2012 | B2 |
| 8212100 | Moore | Jul 2012 | B2 |
| 8215929 | Shen et al. | Jul 2012 | B2 |
| 8323264 | Weston et al. | Dec 2012 | B2 |
| 8371829 | Jaeb et al. | Feb 2013 | B2 |
| 8372049 | Jaeb et al. | Feb 2013 | B2 |
| 8372050 | Jaeb et al. | Feb 2013 | B2 |
| 8404921 | Lee et al. | Mar 2013 | B2 |
| 8409160 | Locke et al. | Apr 2013 | B2 |
| 8414519 | Hudspeth et al. | Apr 2013 | B2 |
| 8419696 | Wilkes | Apr 2013 | B2 |
| 8425478 | Olson | Apr 2013 | B2 |
| 8439894 | Miller | May 2013 | B1 |
| 8449508 | Coulthard et al. | May 2013 | B2 |
| 8500776 | Ebner | Aug 2013 | B2 |
| 8529548 | Blott et al. | Sep 2013 | B2 |
| 8545466 | Andresen et al. | Oct 2013 | B2 |
| 8579872 | Coulthard et al. | Nov 2013 | B2 |
| 8603074 | Kagan | Dec 2013 | B2 |
| 8604265 | Locke et al. | Dec 2013 | B2 |
| 8641691 | Fink et al. | Feb 2014 | B2 |
| 8641693 | Locke et al. | Feb 2014 | B2 |
| 8702665 | Locke et al. | Apr 2014 | B2 |
| 8764732 | Hartwell | Jul 2014 | B2 |
| 8795257 | Coulthard et al. | Aug 2014 | B2 |
| 8808274 | Hartwell | Aug 2014 | B2 |
| 8814842 | Coulthard et al. | Aug 2014 | B2 |
| 8821458 | Locke et al. | Sep 2014 | B2 |
| 8870837 | Locke et al. | Oct 2014 | B2 |
| 8905985 | Allen et al. | Dec 2014 | B2 |
| 8961496 | Locke et al. | Feb 2015 | B2 |
| 8974429 | Gordon et al. | Mar 2015 | B2 |
| 9061095 | Adie et al. | Jun 2015 | B2 |
| 9084845 | Adie et al. | Jul 2015 | B2 |
| 9089630 | Perkins et al. | Jul 2015 | B2 |
| 9198802 | Robinson et al. | Dec 2015 | B2 |
| 9259558 | Tsai | Feb 2016 | B2 |
| 9265665 | Robinson et al. | Feb 2016 | B2 |
| 9283118 | Locke et al. | Mar 2016 | B2 |
| 9393354 | Freedman et al. | Jul 2016 | B2 |
| 9414968 | Heagle | Aug 2016 | B2 |
| 9421133 | Hu et al. | Aug 2016 | B2 |
| 9427505 | Askem et al. | Aug 2016 | B2 |
| 9452088 | Shulman et al. | Sep 2016 | B2 |
| 9560975 | Mei et al. | Feb 2017 | B2 |
| D787690 | MacKay et al. | May 2017 | S |
| 9737649 | Begin et al. | Aug 2017 | B2 |
| 9770368 | Robinson et al. | Sep 2017 | B2 |
| 9814811 | Aalders et al. | Nov 2017 | B2 |
| 9907703 | Allen et al. | Mar 2018 | B2 |
| 9925092 | Luckemeyer et al. | Mar 2018 | B2 |
| RE46778 | Peron | Apr 2018 | E |
| 9956120 | Locke | May 2018 | B2 |
| 10004914 | Nettesheim et al. | Jun 2018 | B2 |
| 10016543 | Pratt et al. | Jul 2018 | B2 |
| 10016544 | Coulthard et al. | Jul 2018 | B2 |
| 10046095 | Middaugh et al. | Aug 2018 | B1 |
| 10046096 | Askem et al. | Aug 2018 | B2 |
| 10086117 | Locke et al. | Oct 2018 | B2 |
| 10485906 | Freedman et al. | Nov 2019 | B2 |
| 11096831 | Askem | Aug 2021 | B2 |
| 20030212357 | Pace | Nov 2003 | A1 |
| 20040076662 | Riesinger | Apr 2004 | A1 |
| 20040087884 | Haddock et al. | May 2004 | A1 |
| 20040167482 | Watson | Aug 2004 | A1 |
| 20050012616 | Forster et al. | Jan 2005 | A1 |
| 20050045461 | Sweetland et al. | Mar 2005 | A1 |
| 20050065471 | Kuntz | Mar 2005 | A1 |
| 20050119737 | Bene et al. | Jun 2005 | A1 |
| 20050137539 | Biggie et al. | Jun 2005 | A1 |
| 20060029650 | Coffey | Feb 2006 | A1 |
| 20060086598 | Sneek et al. | Apr 2006 | A1 |
| 20060107642 | Smith et al. | May 2006 | A1 |
| 20060259102 | Slatkine | Nov 2006 | A1 |
| 20070055209 | Patel et al. | Mar 2007 | A1 |
| 20070128055 | Lee | Jun 2007 | A1 |
| 20070179460 | Adahan | Aug 2007 | A1 |
| 20070225663 | Watt et al. | Sep 2007 | A1 |
| 20070255187 | Branch | Nov 2007 | A1 |
| 20070265586 | Joshi et al. | Nov 2007 | A1 |
| 20080021356 | Castello Escude et al. | Jan 2008 | A1 |
| 20080051716 | Stutz | Feb 2008 | A1 |
| 20090012484 | Nielsen et al. | Jan 2009 | A1 |
| 20090048556 | Durand | Feb 2009 | A1 |
| 20100022990 | Karpowicz et al. | Jan 2010 | A1 |
| 20100100160 | Edman et al. | Apr 2010 | A1 |
| 20100137775 | Hu et al. | Jun 2010 | A1 |
| 20100160881 | Lin et al. | Jun 2010 | A1 |
| 20100280469 | Hall et al. | Nov 2010 | A1 |
| 20100292632 | Mulvihill et al. | Nov 2010 | A1 |
| 20110092927 | Wilkes et al. | Apr 2011 | A1 |
| 20110112492 | Bharti et al. | May 2011 | A1 |
| 20110224631 | Simmons et al. | Sep 2011 | A1 |
| 20110292623 | Stanley | Dec 2011 | A1 |
| 20110305736 | Wieland et al. | Dec 2011 | A1 |
| 20120059294 | Schubert et al. | Mar 2012 | A1 |
| 20120109034 | Locke et al. | May 2012 | A1 |
| 20130215638 | Dabov et al. | Aug 2013 | A1 |
| 20130276144 | Hansen | Oct 2013 | A1 |
| 20140100536 | Angel | Apr 2014 | A1 |
| 20140343518 | Riesinger | Nov 2014 | A1 |
| 20150057625 | Coulthard | Feb 2015 | A1 |
| 20150202354 | Wall | Jul 2015 | A1 |
| 20160015873 | Robinson et al. | Jan 2016 | A1 |
| 20160166438 | Rovaniemi | Jun 2016 | A1 |
| 20160199546 | Chao | Jul 2016 | A1 |
| 20160242964 | Rapp et al. | Aug 2016 | A1 |
| 20160271305 | Kurihara et al. | Sep 2016 | A1 |
| 20160296680 | Simmons et al. | Oct 2016 | A1 |
| 20160361473 | Robinson et al. | Dec 2016 | A1 |
| 20170112974 | Fujisaki | Apr 2017 | A1 |
| 20170112975 | Fujisaki | Apr 2017 | A1 |
| 20170127525 | Schonholz | May 2017 | A1 |
| 20170232189 | Qin et al. | Aug 2017 | A1 |
| 20170296714 | Locke et al. | Oct 2017 | A1 |
| 20170319761 | Locke et al. | Nov 2017 | A1 |
| 20170326277 | Huang | Nov 2017 | A1 |
| 20170368239 | Askem et al. | Dec 2017 | A1 |
| 20180008760 | Zilbershlag et al. | Jan 2018 | A1 |
| 20180021178 | Locke et al. | Jan 2018 | A1 |
| 20180028728 | Aarestad et al. | Feb 2018 | A1 |
| 20180104393 | Wu et al. | Apr 2018 | A1 |
| 20180200414 | Askem et al. | Jul 2018 | A1 |
| 20180272052 | Locke et al. | Sep 2018 | A1 |
| 20180296397 | Askem et al. | Oct 2018 | A1 |
| 20180318137 | Donda et al. | Nov 2018 | A1 |
| 20180318165 | Donda et al. | Nov 2018 | A1 |
| 20180353771 | Kim et al. | Dec 2018 | A1 |
| 20190021911 | Askem et al. | Jan 2019 | A1 |
| 20190125943 | Askem et al. | May 2019 | A1 |
| 20190142644 | Askem et al. | May 2019 | A1 |
| 20190143007 | Askem et al. | May 2019 | A1 |
| 20190159938 | Askem et al. | May 2019 | A1 |
| 20190192350 | Gowans et al. | Jun 2019 | A1 |
| 20190282737 | Beadle et al. | Sep 2019 | A1 |
| 20200022846 | Beadle et al. | Jan 2020 | A1 |
| Number | Date | Country |
|---|---|---|
| 201664463 | Dec 2010 | CN |
| 19844355 | Apr 2000 | DE |
| 0512543 | Nov 1992 | EP |
| 1411874 | Apr 2004 | EP |
| 1455701 | Mar 2006 | EP |
| 1807032 | Jul 2007 | EP |
| 1476217 | Mar 2008 | EP |
| 1976477 | Oct 2008 | EP |
| 1507498 | Jul 2009 | EP |
| 1791579 | Jul 2009 | EP |
| 2109472 | Oct 2009 | EP |
| 1947987 | May 2010 | EP |
| 1358456 | Jul 2010 | EP |
| 2214728 | Aug 2010 | EP |
| 2279016 | Feb 2011 | EP |
| 2326295 | Jun 2011 | EP |
| 2340064 | Jul 2011 | EP |
| 2346468 | Jul 2011 | EP |
| 2349155 | Aug 2011 | EP |
| 2205190 | Sep 2011 | EP |
| 2370116 | Oct 2011 | EP |
| 2531761 | Dec 2012 | EP |
| 2231088 | Jan 2013 | EP |
| 2015655 | Mar 2013 | EP |
| 2285323 | Mar 2013 | EP |
| 2563421 | Mar 2013 | EP |
| 2049055 | Apr 2013 | EP |
| 2340066 | Apr 2013 | EP |
| 2440260 | May 2013 | EP |
| 2340062 | Jun 2013 | EP |
| 2603699 | Jun 2013 | EP |
| 1893145 | Jul 2013 | EP |
| 2370142 | Jul 2013 | EP |
| 2279017 | Aug 2013 | EP |
| 2370117 | Aug 2013 | EP |
| 2258443 | Sep 2013 | EP |
| 2263742 | Sep 2013 | EP |
| 2659915 | Nov 2013 | EP |
| 1848390 | Dec 2013 | EP |
| 1875081 | Dec 2013 | EP |
| 2271381 | Dec 2013 | EP |
| 2160166 | Jan 2014 | EP |
| 1565219 | Feb 2014 | EP |
| 2305325 | Apr 2014 | EP |
| 2323712 | Apr 2014 | EP |
| 2451498 | Apr 2014 | EP |
| 2051675 | Jun 2014 | EP |
| 1485613 | Jul 2014 | EP |
| 1545644 | Aug 2014 | EP |
| 2349154 | Aug 2014 | EP |
| 2146759 | Sep 2014 | EP |
| 2416816 | Oct 2014 | EP |
| 2468323 | Oct 2014 | EP |
| 2658493 | Oct 2014 | EP |
| 1850818 | Dec 2014 | EP |
| 2268348 | Dec 2014 | EP |
| 2561128 | Jan 2015 | EP |
| 2829287 | Jan 2015 | EP |
| 2683285 | Feb 2015 | EP |
| 2470136 | Mar 2015 | EP |
| 2503974 | May 2015 | EP |
| 2249894 | Aug 2015 | EP |
| 2802366 | Aug 2015 | EP |
| 2438302 | Sep 2015 | EP |
| 2346545 | Oct 2015 | EP |
| 2438301 | Oct 2015 | EP |
| 2802304 | Dec 2015 | EP |
| 2852421 | Jan 2016 | EP |
| 2410962 | Mar 2016 | EP |
| 2640436 | Mar 2016 | EP |
| 2855937 | May 2016 | EP |
| 2433594 | Jun 2016 | EP |
| 2919730 | Jun 2016 | EP |
| 2861869 | Jul 2016 | EP |
| 2945584 | Jul 2016 | EP |
| 2293749 | Aug 2016 | EP |
| 2305327 | Oct 2016 | EP |
| 2467086 | Oct 2016 | EP |
| 2470135 | Oct 2016 | EP |
| 2767305 | Oct 2016 | EP |
| 2282788 | Dec 2016 | EP |
| 2462956 | Mar 2017 | EP |
| 3139878 | Mar 2017 | EP |
| 2249761 | Apr 2017 | EP |
| 1587502 | May 2017 | EP |
| 1587554 | May 2017 | EP |
| 2731563 | May 2017 | EP |
| 2968871 | Jul 2017 | EP |
| 2632613 | Aug 2017 | EP |
| 2781208 | Aug 2017 | EP |
| 2888478 | Aug 2017 | EP |
| 2937107 | Aug 2017 | EP |
| 2967627 | Aug 2017 | EP |
| 3062751 | Aug 2017 | EP |
| 3139879 | Aug 2017 | EP |
| 2359784 | Sep 2017 | EP |
| 3151795 | Sep 2017 | EP |
| 2367518 | Oct 2017 | EP |
| 2675493 | Oct 2017 | EP |
| 3068455 | Oct 2017 | EP |
| 2558046 | Nov 2017 | EP |
| 2736548 | Nov 2017 | EP |
| 3052158 | Nov 2017 | EP |
| 2593058 | Mar 2018 | EP |
| 3139880 | Mar 2018 | EP |
| 1496822 | Aug 2018 | EP |
| 2879633 | Aug 2018 | EP |
| 2227203 | Sep 2018 | EP |
| 2696826 | Sep 2018 | EP |
| 3106186 | Sep 2018 | EP |
| 3162330 | Sep 2018 | EP |
| 3169382 | Sep 2018 | EP |
| 3203953 | Sep 2018 | EP |
| 2941280 | Oct 2018 | EP |
| 3244852 | Oct 2018 | EP |
| 2687241 | Nov 2018 | EP |
| 2687243 | Nov 2018 | EP |
| 3062753 | Nov 2018 | EP |
| 3120879 | Dec 2018 | EP |
| 3191149 | Jan 2019 | EP |
| 2370130 | Mar 2019 | EP |
| 3053609 | Mar 2019 | EP |
| 3180048 | Mar 2019 | EP |
| 3143974 | Apr 2019 | EP |
| 2285432 | Jun 2019 | EP |
| 3050545 | Jul 2019 | EP |
| 3319656 | Aug 2019 | EP |
| 2355762 | Sep 2019 | EP |
| 2822613 | Sep 2019 | EP |
| 2863855 | Sep 2019 | EP |
| 2482912 | Oct 2019 | EP |
| 3038667 | Oct 2019 | EP |
| 3129095 | Oct 2019 | EP |
| 3191150 | Oct 2019 | EP |
| 3280466 | Oct 2019 | EP |
| 2244756 | Dec 2019 | EP |
| 2968702 | Dec 2019 | EP |
| 2939320 | Jun 2010 | FR |
| 2511523 | Sep 2014 | GB |
| H04354722 | Dec 1992 | JP |
| 131622 | Aug 2013 | RU |
| WO-2007030601 | Mar 2007 | WO |
| WO-2009098696 | Aug 2009 | WO |
| WO-2009120951 | Oct 2009 | WO |
| WO-2011130570 | Oct 2011 | WO |
| WO-2011135285 | Nov 2011 | WO |
| WO-2011144888 | Nov 2011 | WO |
| WO-2014099709 | Jun 2014 | WO |
| WO-2016126560 | Aug 2016 | WO |
| WO-2017079174 | May 2017 | WO |
| WO-2017196888 | Nov 2017 | WO |
| WO-2018056060 | Mar 2018 | WO |
| WO-2018115461 | Jun 2018 | WO |
| WO-2018156730 | Aug 2018 | WO |
| WO-2018158250 | Sep 2018 | WO |
| WO-2018162613 | Sep 2018 | WO |
| WO-2018164803 | Sep 2018 | WO |
| WO-2018185138 | Oct 2018 | WO |
| WO-2018192978 | Oct 2018 | WO |
| Entry |
|---|
| International Preliminary Report on Patentability for Application No. PCT/EP2017/060464, dated Nov. 15, 2018, 9 pages. |
| International Search Report and Written Opinion for Application No. PCT/EP2017/060464, dated Jul. 4, 2017, 12 pages. |
| Number | Date | Country | |
|---|---|---|---|
| 20210378871 A1 | Dec 2021 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62479615 | Mar 2017 | US | |
| 62331056 | May 2016 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16098625 | US | |
| Child | 17406564 | US |
